67 results about "Activin receptor" patented technology

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.

The present application provides a recombinant fusion protein comprising a human activin receptor 2A extracellular domain optionally fused to an immunoglobulin heavy chain constant region via a linker wherein the human ACVR2A extracellular domain comprises a mutation from Asn (N) to Ala (A) at a site corresponding to position 24 of the sequence as shown in SEQ ID NO: 1 to remove glycosylation sites.

The invention features methods of treating a transfusion dependent subject having myelofibrosis, a cytopenia associated with myelofibrosis, such as anemia, thrombocytopenia, or neutropenia, or receiving treatment with a cytopenia-associated myelofibrosis treatment by administering to the subject an activin receptor type II (ActRII) signaling inhibitor, optionally in combination with a cytopenia- associated myelofibrosis treatment. The ActRII signaling inhibitor may be an antibody that binds to an ActRII ligand, an ActRII antibody, or an ActRII ligand trap.

The invention features methods of treating a subject who is undergoing treatment with or previously underwent treatment with an incretin-based therapy by administering a polypeptide including an activin receptor type II (ActRII) chimera. The extracellular ActRII chimera may be fused to an Fc domain monomer. The incretin-based therapy may be, e.g., a GLP-1 receptor agonist or a DPP-4 inhibitor.

Provided herein, in part, is a method of treating or preventing obesity or an obesity-related disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a small molecule inhibitor of an Activin receptor Type II.

In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and / or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides ActRIIB antagonists for use in treating, preventing, or reducing the progression rate and / or severity of one or more complications associated with Janus kinase inhibitor therapy in a patient (e.g., anemia).

The present invention relates to compounds of formula (I) which are inhibitors of activin receptor-like kinase 5 (ALK5) and related uses.

The present invention relates to novel 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as potent inhibitors of transforming growth factor-beta receptor I (also known as activin receptor-like kinase 5) (TGFβRI) / ALK5. Other objects of the present invention are to provide processes for preparing these compounds; pharmaceutical compositions comprising an effective amount of these compounds; the use of said compounds for the preparation of a medicament for the treatment of pathological conditions or diseases which can be ameliorated by the inhibition of transforming growth factor-beta receptor I (TGFβRI) / ALK5, such as respiratory diseases, including idiopathic pulmonary fibrosis, asthma, COPD and lung cancer and skin and ocular fibrotic disorders.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness or atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, pulmonary hypertension, and / or diseases and conditions that can be treated with erythropoietin or an erythropoiesis-stimulating agent.

In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine / threonine kinase receptor of the TGF-beta family or an extracellular domain of a type II serine / threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble single-arm polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used for the treatment or prevention of various TGF-beta associated conditions, including without limitation diseases and disorders associated with, for example, cancer, muscle, bone, fat, red blood cells, metabolism, fibrosis and other tissues that are affected by one or more ligands of the TGF-beta superfamily.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.

To provide an agent for reducing iron overload in patients having conditions such as beta-thalassaemia and myelodysplastic syndrome (MDS).SOLUTION: Antibodies to enzyme matriptase-2 (MTP-2) are presented. Inhibiting MTP-2 reduces uptake of dietary iron and reduces release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to a serine protease domain) can be used to treat iron overload, which is a feature of diseases such as beta-thalassaemia and which otherwise leads to toxic accumulation of iron. Combination of an MTP-2 inhibitor with an activin receptor ligand trap, or with erythropoeitin, provides additional therapeutic effects.SELECTED DRAWING: Figure 1

The present application relates to an activin receptor II antibody and a use. The activin receptor II antibody comprises a heavy chain CDR1, a heavy chain CDR2, a heavy chain CDR3, a light chain CDR1, a light chain CDR2, and a light chain CDR3. A mutation relative to CDRs of a parental antibody includes one or more selected from the following: a heavy chain CDR2 V54A mutation, a heavy chain CDR2 G56L mutation, a heavy chain CDR2 T58K mutation, a heavy chain CDR3 G99S mutation, a heavy chain CDR3 G99T mutation, a light chain CDR1 G24H mutation, a light chain CDR1 D28W mutation, a light chain CDR1 Y32F mutation, a light chain CDR2 P57E mutation, a light chain CDR3 S97A mutation, and a light chain CDR3 Y99N mutation. A balanced activin receptor II dual-blocking antibody that exhibits higher affinity for ActRIIA while not significantly reducing affinity for ActRIIB is obtained by screening.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an Activin Receptor-Like Kinase 7 (ALK7) gene. The ALK7 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an ALK7 gene. Pharmaceutical compositions that include one or more ALK7 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described ALK7 RNAi agents to adipose tissue, in vivo, provides for inhibition of ALK7 gene expression and a reduction in ALK7 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including obesity, diabetes, or insulin resistance.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of an Activin Receptor-Like Kinase 7 (ALK7) gene. The ALK7 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an ALK7 gene. Pharmaceutical compositions that include one or more ALK7 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described ALK7 RNAi agents to adipose tissue, in vivo, provides for inhibition of ALK7 gene expression and a reduction in ALK7 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including obesity, diabetes, or insulin resistance.

This application provides a heterocyclic compound, a pharmaceutical composition, an activin type II receptor inhibitor, and their applications. The heterocyclic compound is a compound of Formula I or its racemic, stereoisomer, geometric isomer, tautomer, nitride, hydrate, isotope label, solvate, polymorph, metabolite, pharmaceutically acceptable salt, pharmaceutically acceptable ester, or pharmaceutically acceptable prodrug. This heterocyclic compound, pharmaceutical composition, and activin type II receptor inhibitor can effectively inhibit activin receptor 2B with high selectivity, showing promising application prospects in the preparation of anti-cachexia drugs, anti-muscle muscular atrophy drugs, or anti-metabolic disease drugs.

The present invention relates to compounds of formula (I) which are inhibitors of activin receptor-like kinase 5 (ALK5) and related uses.

Methods for treating obesity and related comorbidities, such as type II diabetes, by decreasing body fat mass while increasing lean mass, and thereby decreasing central adiposity, are provided. The method includes administering myostatin or activin or an activin receptor antagonist, preferably an anti-ActRII receptor antibody such as bimagrumab.

Compositions, methods of making and methods of using are provided for topical administration of pharmaceutical compositions comprising one or more activin receptor-like kinase-5 (ALK-5) kinase inhibitors. The pharmaceutical compositions can be used for treatment of diseases and disorders affecting the skin.

The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.

Disclosed herein are methods of deriving, producing, maintaining, or expanding embryonic stem cells (ESCs) from avian species and a culture medium used for such methods. According to various embodiments, the method includes culturing an embryo extracted from an avian egg in a culture medium to harvest cells from yolk of the avian egg; dissociating cells from the cultured embryo; isolating a morphologically undifferentiated ESC colony from the dissociated cells in a culture medium; and culturing the isolated ESC colony in the presence of ovotransferrin, thereby deriving ESCs. According to various embodiments, the culture medium includes a Wnt inhibitor; a protein kinase C (PKC) inhibitor; ovotransferrin; an inhibitor of activin receptor-like kinases-4, -5, and -7; and a leukemia inhibitory factor (LIF).

Provided herein are antibodies and / or antigen-binding fragments thereof that bind to ActRIIA and / or ActRIIB, and methods of using the same.

Antibodies to the enzyme matriptase-2 (MTP-2) are presented. Inhibiting MTP-2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine protease domain) can be used to treat iron overload, which is a feature of diseases such as beta-thalassaemia and which otherwise leads to toxic accumulation of iron. Combination of an MTP-2 inhibitor with an activin receptor ligand trap, or with erythropoietin, provides additional therapeutic effects.

The invention features methods of treating a subject having myelofibrosis by co-administering an activin receptor type II (ActRII) signaling inhibitor and a myelofibrosis therapy. The ActRII signaling inhibitor may be an antibody that binds to an ActRII ligand, an ActRII antibody, an ActRII ligand trap, or an anti-myostatin adnectin recombinant protein.

Provided herein are oligonucleotides for inhibiting the expression of Activin receptor 2B (ACVR2B) and methods of using the oligonucleotides for reducing ACVR2B expression in a subject.

A method of diagnosing pancreatic ductal adenocarcinoma (PDAC) comprising detecting an autoantibody of GAGE1 (G antigen 1, GAGE4) and an autoantibody of ACVR2B (activin A receptor type 2B). Also claimed is a method of diagnosing PDAC comprising detecting an antibody which binds to LEMD1, MAGEB1, PAGE1, TSGA10, BAGE4, AURKA, MAGEA10, PLEKHA5, PLK4, XAGE3Av1. The autoantibodies may be IgA and / or IgG antibodies. The method may comprise contacting a sample with GAGE1 and ACVR2B antigens and detecting the binding of antibodies to the antigens. The levels of antibodies may be quantified and compared to healthy subjects or those with chronic pancreatitis. The antigens may be bound to a support, such as a bead, membrane, slide, plate, well, filter, or dipstick. The method may comprise detecting GAGE1, ACVR2B and other additional antigens. Also claimed is an antigen complex comprising a biotin carboxyl carrier protein (BCCP)-tagged antigen bound to a support, wherein the antigen is GAGE1, and wherein the support is coated with streptavidin, for use in the method. A kit comprising GAGE1 and another antigen. Also claimed is a computer implemented method of diagnosing PDAC comprising comparing data comprising the number of antibodies detected to reference data and displaying a diagnosis.

The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.

To provide polypeptides and pharmaceutical compositions comprising activin type IIB receptor variants.SOLUTION: The polypeptide of the present invention comprises an extracellular activin type IIB receptor (ActRIIB) mutant comprising an amino acid sequence consisting of a specific sequence, wherein the C-terminus of the ActRIIB mutant is fused to a human IgG1Fc domain monomer. The invention also features pharmaceutical compositions and methods of using the same to treat diseases and conditions involving muscle weakness and atrophy, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and / or pulmonary hypertension.SELECTED DRAWING: Figure 2